Analysing the effect of multidisciplinary teams to address preventive healthcare gaps in a rural teaching clinic: a quality improvement project [PDF]
BMJ Open QualityPreventive care decreases the risk of illness, disease and death, yet patient adherence to preventive care is low, calculated to be around 5%, and rural residents are suspected to have even lower rates compared with urban patients.
Veronica Hill +4 more
doaj +2 more sources
Research Progress on Varicella-Zoster Virus Vaccines [PDF]
VaccinesVaricella-zoster virus (VZV) poses significant public health challenges as the etiological agent of varicella (chickenpox) and herpes zoster (HZ), given its high transmissibility and potential for severe complications.
Hongjing Liu +11 more
doaj +2 more sources
Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice [PDF]
VirusesVaricella-zoster virus (VZV) is a human neurotropic herpesvirus. The primary infection with VZV causes chickenpox and establishes latency in sensory and dorsal root ganglia.
Yaru Quan +7 more
doaj +2 more sources
Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination
ReportsBackground and Clinical Significance: The recombinant zoster vaccine (Shingrix) helps prevent shingles and its complications in adults 50 and older. While minor side effects are common, severe adverse reactions are thought to be rare, and long-term side ...
Sabrina Hollar +3 more
doaj +2 more sources
Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024 [PDF]
Frontiers in MedicineBackgroundHerpes Zoster (HZ) is a viral skin disease caused by reactivation of latent Varicella Zoster Virus (VZV) in human ganglia, presenting with unilateral neuropathic pain and vesicular rash.
Wenli Gao +5 more
doaj +2 more sources
The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018–2024 [PDF]
Human Vaccines & ImmunotherapeuticsThis post-marketing safety study evaluated the co-administration of recombinant zoster vaccine (RZV, Shingrix) and influenza vaccines (HD-IIV/aIIV/RIV) in adults aged ≥ 65 years using U.S. VAERS data (2018–2024).
Yihao Li +6 more
doaj +2 more sources
Development and Evaluation of the Immunogenic Potential of an Unmodified Nucleoside mRNA Vaccine for Herpes Zoster [PDF]
VaccinesBackground/Objectives: Approved mRNA vaccines commonly use sequences modified with pseudouridine to enhance translation efficiency and mRNA stability.
Shun Zhang +4 more
doaj +2 more sources
National Trends and Disparities in Herpes Zoster Vaccination Among US Older Adults With Diabetes, 2008-2023. [PDF]
Pharmacoepidemiol Drug SafABSTRACT Purpose To evaluate trends and disparities in herpes zoster vaccination among US older adults with diabetes. Methods Data from the 2008 to 2023 National Health Interview Survey were used. Joinpoint regression analysis was performed to analyze trends in herpes zoster vaccination.
Hung CT, Wang LM, Liu DC, Hung YC.
europepmc +2 more sources
An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21
npj Vaccines, 2022 Herpes zoster (HZ) is caused by reactivation of latent varicella-zoster virus (VZV) when VZV-specific cellular immunity is insufficient to control reactivation.
Hyo Jung Nam +9 more
doaj +1 more source
Evaluation of Shingrix vaccine against Herpes Zoster
, 2022 173 p. ill., 1 BACKGROUND 18 -- 1.1 HERPES ZOSTER .18 -- 1.2 TREATMENT .20 -- 1.3 VACCINE .21 -- 2 RESEARCH QUESTIONS .22 -- 3 BURDEN OF DISEASE OF HZ IN BELGIUM .22 -- 3.1 METHODS 22 -- 3.2 INCIDENCE OF HZ 22 -- 3.2.1 Belgian data 23 -- 3.2.2 International data .34 -- 3.2.3 Risk of recurrence 42 -- 3.2.4 Discussion 42 -- 3.3 INCIDENCE OF POSTHERPETIC ...
Dominique, Roberfroid +3 more
+5 more sources